Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADYNOVATE prophylaxis and on-demand treatment in previously treated Chinese patients with severe hemophilia A
CTR20223385Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant coagulation factor viii in hemophilia A, sponsored by Takeda. Primary endpoint: Annualized bleeding rate for all bleeding events. Started Jan 2023; status: completed.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20223385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223385.